House
GuidelinesCalculatorsPricingBlog
Ask House ↗
Guidelines↗Calculators↗Pricing↗Blog↗
House
Clinical AIRoundsGuidelinesCalculatorsPricingBlogAboutEditorial policyPrivacyTermsLog in ↗
Clinical intelligence, for physicians.© 2026 House
House
Clinical AIRoundsGuidelinesCalculatorsPricingBlogAboutEditorial policyPrivacyTermsLog in ↗
Clinical intelligence, for physicians.© 2026 House
Back to guidelines
Nephrology

Chronic kidney disease: assessment and management

NICE · 2021 edition / updateSource checked 29 October 2026
Read the source publication
House clinical summary

Scope

NICE NG203 organizes chronic kidney disease care around combined eGFR and albuminuria assessment, investigation of cause, individualized monitoring and timely specialist referral. Adult treatment depends on albuminuria, diabetes, blood pressure and kidney function, with laboratory surveillance essential during renin–angiotensin-system treatment. This summary concentrates on recognition, risk assessment and kidney-protective care, and preserves separate paediatric referral criteria rather than applying adult thresholds to children.

Written by House with AI assistance · AI-assisted source check 29 October 2026.

This is House’s summary of the cited guidance. The source check is not an independent clinician review. Open the publication for complete recommendations, exceptions, evidence grades and later amendments.

Identify CKD and confirm abnormal results

  • Test at-risk adults with both creatinine-based eGFR and urine ACR. Important triggers include diabetes, hypertension, prior acute kidney injury, cardiovascular or structural renal disease, gout, a family history of kidney failure and incidental haematuria or proteinuria. [1]
  • Repeat a newly found adult eGFR below 60 ml/min/1.73 m² within 2 weeks. Interpret creatinine-based estimates cautiously with unusual muscle mass, and distinguish acute deterioration from persistent kidney disease. [1]
  • Use urine ACR for initial proteinuria assessment. Confirm values from 3 to 70 mg/mmol with an early-morning sample; no repeat is needed at 70 mg/mmol or above. A confirmed ACR of at least 3 mg/mmol is clinically important. [1]
  • After acute kidney injury, monitor for CKD development or progression for at least 3 years even if eGFR returns to baseline; continue longer after stage 3 acute kidney injury. [1]

Classify risk and establish the cause

  • Classify adult CKD using both GFR and ACR categories. Reduced GFR and increased albuminuria together multiply adverse-outcome risk. Agree a plan to identify treatable causes, including obstruction, nephrotoxic medicines or glomerular disease. [1]
  • Offer renal ultrasound to adults with CKD who have accelerated progression, visible or persistent invisible haematuria, obstructive symptoms, GFR below 30 ml/min/1.73 m², a family history of polycystic kidney disease when older than 20, or a nephrologist’s indication for biopsy. [1]
  • Agree individualized eGFR and ACR monitoring. Determine progression from at least 3 GFR estimates over at least 90 days, and repeat a newly reduced GFR within 2 weeks to assess for acute deterioration. [1]
  • For adults with CKD, encourage exercise, healthy weight and smoking cessation. Tailor potassium, phosphate, calorie and salt advice to disease severity, with dietary assessment and supervision to prevent malnutrition. [1]

Use kidney-failure risk and clinical features for referral

  • Explain the adult 5-year kidney-replacement risk using the 4-variable Kidney Failure Risk Equation. A risk above 5% is one specialist-referral criterion, applied with the person’s wishes and comorbidities. [1]
  • Refer adults with ACR at least 70 mg/mmol unless it is attributable to diabetes and already appropriately treated, or with ACR above 30 mg/mmol plus haematuria. These are separate referral triggers. [1]
  • Other adult referral triggers include a sustained eGFR fall of at least 25% with category change within 12 months, a sustained fall of at least 15 ml/min/1.73 m² per year, hypertension uncontrolled despite at least 4 therapeutic-dose agents, suspected rare/genetic disease or renal artery stenosis. [1]
  • Refer children and young people with CKD for confirmed early-morning ACR of at least 3 mg/mmol, haematuria, any eGFR reduction, hypertension, rare/genetic disease, suspected renal artery stenosis or outflow obstruction. [1]

Match adult treatment to albuminuria and comorbidity

  • For adults with CKD and ACR below 70 mg/mmol, aim for clinic blood pressure below 140/90 mmHg, with systolic range 120–139. At ACR 70 mg/mmol or above, aim below 130/80, with systolic range 120–129. Frailty and multimorbidity require individualized application. [1]
  • Offer an ACE inhibitor or ARB at the highest tolerated licensed dose when CKD accompanies hypertension and ACR above 30 mg/mmol. In adults with diabetes, offer one when ACR is at least 3 mg/mmol. [1]
  • For adults without diabetes, ACR of at least 70 mg/mmol warrants nephrology assessment and an ACE inhibitor or ARB at the highest tolerated licensed dose. At ACR above 30 but below 70, monitor and consider nephrology discussion if eGFR falls or ACR rises. [1]
  • NICE lists SGLT2 inhibitors as options added to optimized standard care for adult CKD with eGFR 20 to below 45 ml/min/1.73 m², or eGFR 45–90 with ACR at least 22.6 mg/mmol or type 2 diabetes. Standard care includes the highest tolerated licensed ACE-inhibitor or ARB dose unless contraindicated. [1]
  • Finerenone is an option for adults with type 2 diabetes and stage 3–4 CKD, ACR at least 3 mg/mmol and eGFR at least 25 ml/min/1.73 m². It is added to optimized ACE-inhibitor or ARB plus SGLT2-inhibitor treatment unless those medicines are unsuitable. [1]

Monitor kidney-protective treatment safely

  • Do not combine renin–angiotensin-system antagonists in adult CKD. Check potassium and eGFR before starting treatment, again after 1–2 weeks and after each dose increase. [1]
  • For adults with CKD, do not routinely start a renin–angiotensin antagonist when pretreatment potassium exceeds 5.0 mmol/litre. Address other causes of hyperkalaemia and recheck. Stop the antagonist if potassium reaches 6.0 mmol/litre or more after other potassium-raising medicines have been discontinued. [1]
  • For adults with CKD, after starting or increasing a renin–angiotensin antagonist, an eGFR fall below 25% or creatinine rise below 30% should prompt repeat testing after 1–2 weeks rather than dose modification. For an eGFR fall of at least 25% or creatinine rise of at least 30%, investigate volume depletion or concurrent medicines; if no cause is found, reduce or stop the antagonist. [1]
  • Use NSAIDs cautiously in adults with CKD and monitor their effect on GFR, particularly with low baseline function or other progression risks. Prolonged use may contribute to progression; acute use may reversibly reduce GFR. [1]
  • In adults, children and young people with CKD, consider investigating and managing anaemia when haemoglobin is 110 g/litre or less, or 105 g/litre or less in children under 2 years, or when attributable symptoms develop. [1]

Limitations and use

  • The detailed anaemia, iron, erythropoiesis-stimulating-agent, mineral-bone, acidosis and renal-replacement pathways are not reproduced.
  • Paediatric blood-pressure and non-diabetic proteinuria treatment thresholds are not supplied here: the source prints inconsistent ACR units in those recommendations. Adult treatment thresholds must not be substituted.
  • Drug options are NICE recommendations; full product contraindications, monitoring and local availability still govern prescribing. This summary does not reproduce the complete monitoring-frequency table.

This summary is selective and does not reproduce every recommendation. Apply the source’s population, setting and eligibility criteria, together with clinical judgement and local policy.

Summary sources

  1. 1
    Chronic kidney disease: assessment and management

    Selected recommendation material consulted

Original guideline

Publication details

Issuing organisation
NICE
First published
25 August 2021
Publisher’s latest update
24 November 2021
Resource type
Clinical guideline · House clinical summary

Earlier House summaries: chronic kidney disease assessment and management nice

The source check confirms publication details and the linked edition. It does not certify every recommendation or its suitability for an individual patient. Publisher access conditions may apply.

On this page

  • Scope
  • Identify CKD and confirm abnormal results
  • Classify risk and establish the cause
  • Use kidney-failure risk and clinical features for referral
  • Match adult treatment to albuminuria and comorbidity
  • Monitor kidney-protective treatment safely
  • Limitations and use
  • Summary sources
  • Publication details
House
Clinical AIRoundsGuidelinesCalculatorsPricingBlogAboutEditorial policyPrivacyTermsLog in ↗
Clinical intelligence, for physicians.© 2026 House